



Ref: Syn/CS/SE/PR/2024-25/Mar/10

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

March 19, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled **“Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.”**.

The above-mentioned press release will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Head Legal, Company Secretary & Compliance Officer

Enclosed: Press Release

Press Release**Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.**

Bengaluru, March 19, 2025: Syngene International Limited ('Syngene'), today announced the conclusion of the acquisition of its first biologics site in the USA, which was announced on March 10, 2025. The state-of-the-art biologics facility, fitted with multiple monoclonal antibody (mAbs) manufacturing lines, was acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc., at a gross value of USD 36.5 million.

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. Additionally, it will provide Syngene's customers with continuity of supply from its four development and manufacturing facilities located in India and North America, offering services ranging from cell line development, process optimization and both clinical and commercial supply.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.2 Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company's latest Environmental, Social, and Governance (ESG) report, visit <https://esgreport.syngeneintl.com>.

Contact details

Investor Contacts	Media Contacts
Krishnan G / Nandini Agarwal M: +91 9819992927 / +91 7838382527 E: Krishnan.g@syngeneintl.com E: Nandini.agarwal@syngeneintl.com	Shotorupa Ghosh / Vijay Jeevanandham M: +91 8450977080/ +91 7760759922 E: Shotorupa.ghosh@syngeneintl.com E: Vijay.jeevanandham@syngeneintl.com